Long-term value creation in the pharmaceutical sector: an event study analysis of big pharma stocks
Andrija Tomovic and
International Journal of Sustainable Economy, 2012, vol. 4, issue 4, 370-389
We investigate the drivers of value creation in big pharmaceutical firms. We use a unique dataset of a total of 2,200 news items on research and development (R%D) progress announcements and dividend news of 25 largest pharmaceutical companies for the period 1998-2010. Our findings affirm the role of successful R%D as a driver of value creation in the long-run. This long term view of value creation has implications for sustainability. R%D is a critical input to long-term sustainable growth and the pharmaceutical sector is one of the highest R%D-intense sectors. Furthermore, successful R%D leading to the discovery of new drugs enhances the prospects for a sustainable economy by improving the society's health status and well-being. Indeed, we find that negative R%D news destroys more long-term value than the value created by positive news. This highlights the concern for the overall long-term adverse implications of unsuccessful R%D on the economy.
Keywords: research and development; R%D progress announcements; dividend news; pharmaceutical industry; stock markets; sustainable value creation; event study; sustainable development; dividends; sustainable economy; drug discovery; long-term value. (search for similar items in EconPapers)
References: Add references at CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
Access to full text is restricted to subscribers.
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:ids:ijsuse:v:4:y:2012:i:4:p:370-389
Access Statistics for this article
More articles in International Journal of Sustainable Economy from Inderscience Enterprises Ltd
Bibliographic data for series maintained by Sarah Parker ().